In familial forms of AD, plasma NfL levels have been shown to increase as early as 16 years prior to the expected onset of symptoms in mutation carriers, suggesting its role as an early biomarker of disease conversion [28]. This evidence concerns the gene NEFL and Alzheimer disease.